Advances in the targeting molecules modified chitosan-based nanoformulations

Current Drug Targets

Volumn 14, Issue 9, 2013, Pages 1034-1052

  Du, Hongliang ^a   Cai, Xiaoqing ^a   Zhai, Guangxi ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Chitosan; Conjugation strategies; Diagnosis and treatment; Nanoformulations; Targeted delivery; Targeting molecules

Indexed keywords

AMINOLEVULINIC ACID; APTAMER; ASIALOGLYCOPROTEIN RECEPTOR; CHITOSAN DERIVATIVE; CHLORPROMAZINE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GALACTOSE; INTERLEUKIN 12; INTERLEUKIN 21; LECTIN; MAGNETIC NANOPARTICLE; MANNOSE RECEPTOR; METHOTREXATE; NANOCARRIER; OLIGOMYCIN; ORIDONIN; OVALBUMIN; PACLITAXEL; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RHODAMINE B; TRANSACTIVATOR PROTEIN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; VINCRISTINE;

ATOMIC ABSORPTION SPECTROMETRY; BLOOD BRAIN BARRIER; CELL VIABILITY; COLON CANCER; CYTOTOXICITY; DEGENERATIVE DISEASE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; GENE TARGETING; HUMAN; HYDROPHOBICITY; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PROTEIN EXPRESSION; REVIEW; ZETA POTENTIAL;

ANTIBODIES; CARBOHYDRATES; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DRUG DELIVERY SYSTEMS; FOLIC ACID; HUMANS; NANOCAPSULES; PEPTIDES; PHARMACEUTICAL PREPARATIONS;

EID: 84881361575     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450111314090012     Document Type: Review

References (128)

1. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22(2): 151-85.
2. Moreno-Aspitia A, Perez EA. Anthracycline- and/or taxaneresistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends. Clin Ther 2009; 31(8): 1619-40.
3. Shikanov A, Shikanov S, Vaisman B, Golenser J, Domb AJ. Paclitaxel tumor biodistribution and efficacy after intratumoral injection of a biodegradable extended release implant. Int J Pharm 2008; 358(1-2): 114-20.
4. Vader P, Fens MH, Sachini N, et al. Taxol((R))-induced phosphatidylserine exposure and microvesicle formation in red blood cells is mediated by its vehicle Cremophor((R)) EL. Nanomedicine (Lond) 2013; xxx: xxx-xxx.
5. Wang X, Zhou J, Wang Y, et al. A phase I clinical and pharmacokinetic study of paclitaxel liposome infused in non-small cell lung cancer patients with malignant pleural effusions. Eur J Cancer 2010; 46(8): 1474-80.
6. Benival DM, Devarajan PV. Lipomer of doxorubicin hydrochloride for enhanced oral bioavailability. Int J Pharm 2012; 423(2): 554-61.
7. Devarajan PV, Jindal AB, Patil RR, Mulla F, Gaikwad RV, Samad A. Particle shape: a new design parameter for passive targeting in splenotropic drug delivery. J Pharm Sci 2010; 99(6): 2576-81.
8. Ray A, Larson N, Pike DB, et al. Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates. Mol Pharm 2011; 8(4): 1090-9.
9. Slavoff SA, Saghatelian A. Discovering ligand-receptor interactions. Nat Biotechnol 2012; 30(10): 959-61.
10. Chattopadhyay N, Fonge H, Cai Z, et al. Role of Antibody- Mediated Tumor Targeting and Route of Administration in Nanoparticle Tumor Accumulation in vivo. Mol Pharm 2012; xxx: xxx-xxx.
11. Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2013; 34(4): 1270-80.
12. Kolhatkar R, Lote A, Khambati H. Active tumor targeting of nanomaterials using folic acid, transferrin and integrin receptors. Curr Drug Discov Technol 2011; 8(3): 197-206.
13. Basile L, Pignatello R, Passirani C. Active targeting strategies for anticancer drug nanocarriers. Curr Drug Deliv 2012; 9(3): 255-68.
14. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev 2008; 60(15): 1615-26.
15. Nicolas J, Mura S, Brambilla D, Mackiewicz N, Couvreur P. Design, functionalization strategies and biomedical applications of targeted biodegradable/biocompatible polymer-based nanocarriers for drug delivery. Chem Soc Rev 2013; 42(3): 1147-235.
16. Bernkop-Schnurch A, Dunnhaupt S. Chitosan-based drug delivery systems. Eur J Pharm Biopharm 2012; 81(3): 463-9.
17. Chayed S, Winnik FM. In vitro evaluation of the mucoadhesive properties of polysaccharide-based nanoparticulate oral drug delivery systems. Eur J Pharm Biopharm 2007; 65(3): 363-70.
18. Yang D, Gao X, Qiao J, Nie J. Genipin-crosslinked Ncarboxymethyl chitosan microcapsules prepared by electrostatic spray method. J Control Release 2011; 152 Suppl 1: e252-3.
19. Shi L, Tang C, Yin C. Glycyrrhizin-modified O-carboxymethyl chitosan nanoparticles as drug vehicles targeting hepatocellular carcinoma. Biomaterials 2012; 33(30): 7594-604.
20. Germershaus O, Mao S, Sitterberg J, Bakowsky U, Kissel T. Gene delivery using chitosan, trimethyl chitosan or polyethylenglycolgraft- trimethyl chitosan block copolymers: establishment of structure-activity relationships in vitro. J Control Release 2008; 125(2): 145-54.
21. Lee J, Lee C, Kim TH, et al. Self-assembled glycol chitosan nanogels containing palmityl-acylated exendin-4 peptide as a longacting anti-diabetic inhalation system. J Control Release 2012; 161(3): 728-34.
22. Luo H, Su H, Wang X, Wang L, Li J. N-Succinyl-chitosan nanoparticles induced mitochondria-dependent apoptosis in K562. Mol Cell Probes 2012; 26(4): 164-9.
23. Hohne S, Frenzel R, Heppe A, Simon F. Hydrophobic chitosan microparticles: heterogeneous phase reaction of chitosan with hydrophobic carbonyl reagents. Biomacromolecules 2007; 8(7): 2051-8.
24. Le Tien C, Lacroix M, Ispas-Szabo P, Mateescu MA. N-acylated chitosan: hydrophobic matrices for controlled drug release. J Control Release 2003; 93(1): 1-13.
25. Yu H, Chen X, Lu T, et al. Poly(L-lysine)-graft-chitosan copolymers: synthesis, characterization, and gene transfection effect. Biomacromolecules 2007; 8(5): 1425-35.
26. Wang W, Yao J, Zhou JP, et al. Urocanic acid-modified chitosanmediated p53 gene delivery inducing apoptosis of human hepatocellular carcinoma cell line HepG2 is involved in its antitumor effect in vitro and in vivo. Biochem Biophys Res Commun 2008; 377(2): 567-72.
27. Liu L, Bai Y, Zhu D, et al. Evaluation of the impact of argininechitosan/ DNA nanoparticles on human naive CD4+ T cells. J Biomed Mater Res A 2011; 96(1): 170-6.
28. Wong K, Sun G, Zhang X, et al. PEI-g-chitosan, a novel gene delivery system with transfection efficiency comparable to polyethylenimine in vitro and after liver administration in vivo. Bioconjug Chem 2006; 17(1): 152-8.
29. Jin YH, Hu HY, Qiao MX, et al. pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation. Colloids Surf B Biointerfaces 2012; 94: 184-91.
30. Elsaid N, Jackson TL, Gunic M, Somavarapu S. Positively charged amphiphilic chitosan derivative for the transscleral delivery of rapamycin. Invest Ophthalmol Vis Sci 2012; 53(13): 8105-11.
31. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2013; 48(3): 416-27.
32. Xu S, Olenyuk BZ, Okamoto CT, Hamm-Alvarez SF. Targeting receptor-mediated endocytotic pathways with nanoparticles: Rationale and advances. Adv Drug Deliv Rev 2013; 65(1): 121-38.
33. Webster DM, Sundaram P, Byrne ME. Injectable nanomaterials for drug delivery: Carriers, targeting moieties, and therapeutics. Eur J Pharm Biopharm 2013; xxx: xxx-xxx.
34. Steichen SD, Caldorera-Moore M, Peppas NA. A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics. Eur J Pharm Sci 2012; 48(3): 416-27.
35. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010; 146(3): 264-75.
36. Polson AG, Calemine-Fenaux J, Chan P, et al. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. Cancer Res 2009; 69(6): 2358-64.
37. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm 2009; 6(4): 1041-51.
38. Na K, Sethuraman VT, Bae YH. Stimuli-sensitive polymeric micelles as anticancer drug carriers. Anticancer Agents Med Chem 2006; 6(6): 525-35.
39. Hou Z, Zhan C, Jiang Q, et al. Both FA- and mPEG-conjugated chitosan nanoparticles for targeted cellular uptake and enhanced tumor tissue distribution. Nanoscale Res Lett 2011; 6(1): 563.
40. De P, Gondi SR, Sumerlin BS. Folate-conjugated thermoresponsive block copolymers: highly efficient conjugation and solution selfassembly. Biomacromolecules 2008; 9(3): 1064-70.
41. Alex SM, Rekha MR, Sharma CP. Spermine grafted galactosylated chitosan for improved nanoparticle mediated gene delivery. Int J Pharm 2011; 410(1-2): 125-37.
42. Kim JH, Minai-Tehrani A, Kim YK, et al. Suppression of tumor growth in H-ras12V liver cancer mice by delivery of programmed cell death protein 4 using galactosylated poly(ethylene glycol)- chitosan-graft-spermine. Biomaterials 2012; 33(6): 1894-902.
43. Clark D, Mao L. Cancer biomarker discovery: lectin-based strategies targeting glycoproteins. Dis Markers 2012; 33(1): 1-10.
44. Gajbhiye V, Gong S. Lectin functionalized nanocarriers for gene delivery. Biotechnol Adv 2013; xxx: xxx-xxx.
45. Napoletano C, Zizzari IG, Rughetti A, et al. Targeting of macrophage galactose-type C-type lectin (MGL) induces DC signaling and activation. Eur J Immunol 2012; 42(4): 936-45.
46. Rieger J, Freichels H, Imberty A, et al. Polyester nanoparticles presenting mannose residues: toward the development of new vaccine delivery systems combining biodegradability and targeting properties. Biomacromolecules 2009; 10(3): 651-7.
47. Rigopoulou EI, Roggenbuck D, Smyk DS, et al. Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found. Autoimmun Rev 2012; 12(2): 260-9.
48. Wang Q, Zhang L, Hu W, et al. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomedicine 2010; 6(2): 371-81.
49. Cheng M, Li Q, Wan T, et al. Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo. J Biomed Mater Res B Appl Biomater 2011; 99(1): 70-80.
50. Jiang H, Wu H, Xu YL, Wang JZ, Zeng Y. Preparation of galactosylated chitosan/tripolyphosphate nanoparticles and application as a gene carrier for targeting SMMC7721 cells. J Biosci Bioeng 2011; 111(6): 719-24.
51. Jiang HL, Kwon JT, Kim EM, et al. Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J Control Release 2008; 131(2): 150-7.
52. Dong L, Gao S, Diao H, Chen J, Zhang J. Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells instead of hepatocytes in vivo. J Biomed Mater Res A 2008; 84(3): 777-84.
53. Duan C, Gao J, Zhang D, et al. Galactose-decorated pH-responsive nanogels for hepatoma-targeted delivery of oridonin. Biomacromolecules 2011; 12(12): 4335-43.
54. Wei W, Yue ZG, Qu JB, Yue H, Su ZG, Ma GH. Galactosylated nanocrystallites of insoluble anticancer drug for liver-targeting therapy: an in vitro evaluation. Nanomedicine (Lond) 2010; 5(4): 589-96.
55. Lin WJ, Chen TD, Liu CW. Synthesis and characterization of lactobionic acid grafted pegylated chitosan and nanoparticle complex application. Polymer 2009; 50(17): 4166-74.
56. Diebold SS, Plank C, Cotten M, Wagner E, Zenke M. Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat Cell Mol Genet 2002; 27(1-6): 65-74.
57. Kim TH, Jin H, Kim HW, Cho MH, Cho CS. Mannosylated chitosan nanoparticle-based cytokine gene therapy suppressed cancer growth in BALB/c mice bearing CT-26 carcinoma cells. Mol Cancer Ther 2006; 5(7): 1723-32.
58. Kim TH, Nah JW, Cho MH, Park TG, Cho CS. Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J Nanosci Nanotechnol 2006; 6(9- 10): 2796-803.
59. Jiang HL, Kim YK, Arote R, et al. Mannosylated chitosan-graftpolyethylenimine as a gene carrier for Raw 264.7 cell targeting. Int J Pharm 2009; 375(1-2): 133-9.
60. Hashimoto M, Morimoto M, Saimoto H, et al. Gene transfer by DNA/mannosylated chitosan complexes into mouse peritoneal macrophages. Biotechnol Lett 2006; 28(11): 815-21.
61. Zhu L, Chen L, Cao QR, Chen D, Cui J. Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system. J Control Release 2011; 152 Suppl 1: e190-1.
62. Li P, Wang Y, Zeng F, Chen L, Peng Z, Kong LX. Synthesis and characterization of folate conjugated chitosan and cellular uptake of its nanoparticles in HT-29 cells. Carbohydr Res 2011; 346(6): 801-6.
63. Zu Y, Zhao Q, Zhao X, Zu S, Meng L. Process optimization for the preparation of oligomycin-loaded folate-conjugated chitosan nanoparticles as a tumor-targeted drug delivery system using a twolevel factorial design method. Int J Nanomedicine 2011; 6: 3429-41.
64. Gong JL, Wang SM, Hu XG, Cao MM, Zhang JR. [Synthesis and characterization of folic acid-conjugated chitosan nanoparticles as a tumor-targeted drug carrier] Nan Fang Yi Ke Da Xue Xue Bao 2008; 28(12): 2183-6.
65. Sahu SK, Mallick SK, Santra S, Maiti TK, Ghosh SK, Pramanik P. In vitro evaluation of folic acid modified carboxymethyl chitosan nanoparticles loaded with doxorubicin for targeted delivery. J Mater Sci Mater Med 2010; 21(5): 1587-97.
66. Sahu SK, Maiti S, Maiti TK, Ghosh SK, Pramanik P. Hydrophobically modified carboxymethyl chitosan nanoparticles targeted delivery of paclitaxel. J Drug Target 2011; 19(2): 104-13.
67. Shi Q, Wang H, Tran C, et al. Hydrodynamic delivery of chitosanfolate- DNA nanoparticles in rats with adjuvant-induced arthritis. J Biomed Biotechnol 2011; 2011: 148763.
68. Mansouri S, Cuie Y, Winnik F, et al. Characterization of folatechitosan- DNA nanoparticles for gene therapy. Biomaterials 2006; 27(9): 2060-5.
69. Jreyssaty C, Shi Q, Wang H, et al. Efficient Nonviral Gene Therapy Using Folate-Targeted Chitosan-DNA Nanoparticles In vitro. ISRN Pharm 2012; 2012: 369270.
70. Zheng Y, Cai Z, Song X, et al. Receptor mediated gene delivery by folate conjugated N-trimethyl chitosan in vitro. Int J Pharm 2009; 382(1-2): 262-9.
71. Gao WH, Liu ST, Fan CX, Qi LY, Chen ZL. [Pharmacokinetics, tissue distribution and magnetic resonance's response characterstics of folic acid-O-carboxymethyl chitosan ultrasmall superparamagnetic iron oxide nanoparticles in mice and rats] Yao Xue Xue Bao 2011; 46(7): 845-51.
72. Bhattacharya D, Das M, Mishra D, et al. Folate receptor targeted, carboxymethyl chitosan functionalized iron oxide nanoparticles: a novel ultradispersed nanoconjugates for bimodal imaging. Nanoscale 2011; 3(4): 1653-62.
73. Zheng Y, Cai Z, Song X, et al. Preparation and characterization of folate conjugated N-trimethyl chitosan nanoparticles as protein carrier targeting folate receptor: in vitro studies. J Drug Target 2009; 17(4): 294-303.
74. Yang SJ, Lin FH, Tsai HM, et al. Alginate-folic acid-modified chitosan nanoparticles for photodynamic detection of intestinal neoplasms. Biomaterials 2011; 32(8): 2174-82.
75. Jiang HL, Xu CX, Kim YK, et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graftpolyethylenimine/ Akt1 shRNA complexes through the Akt signaling pathway. Biomaterials 2009; 30(29): 5844-52.
76. Morris VB, Sharma CP. Folate mediated histidine derivative of quaternised chitosan as a gene delivery vector. Int J Pharm 2010; 389(1-2): 176-85.
77. Wang F, Chen Y, Zhang D, et al. Folate-mediated targeted and intracellular delivery of paclitaxel using a novel deoxycholic acid- O-carboxymethylated chitosan-folic acid micelles. Int J Nanomedicine 2012; 7: 325-37.
78. Zhu H, Liu F, Guo J, Xue J, Qian Z, Gu Y. Folate-modified chitosan micelles with enhanced tumor targeting evaluated by near infrared imaging system. Carbohydr Polym 2011; 86(3): 1118-29.
79. Wang H, Zhao P, Liang X, et al. Folate-PEG coated cationic modified chitosan-Cholesterol liposomes for tumor-targeted drug delivery. Biomaterials 2010; 31(14): 4129-38.
80. Shen JM, Tang WJ, Zhang XL, Chen T, Zhang HX. A novel carboxymethyl chitosan-based folate/Fe3O4/CdTe nanoparticle for targeted drug delivery and cell imaging. Carbohydr Polym 2012; 88(1): 239-49.
81. Garnier B, Tan S, Gounou C, et al. Development of a platform of antibody-presenting liposomes. Biointerphases 2012; 7(1-4): 11.
82. Yousefpour P, Atyabi F, Vasheghani-Farahani E, Movahedi AA, Dinarvand R. Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab. Int J Nanomedicine 2011; 6: 1977-90.
83. Torrecilla D, Lozano MV, Lallana E, et al. Anti-tumor efficacy of chitosan-g-poly(ethylene glycol) nanocapsules containing docetaxel: Anti-TMEFF-2 functionalized nanocapsules vs. nonfunctionalized nanocapsules. Eur J Pharm Biopharm 2012; xxx: xxx-xxx. [Epub ahead of print]
84. Lee J, Yun KS, Choi CS, et al. T Cell-Specific siRNA Delivery Using Antibody-Conjugated Chitosan Nanoparticles. Bioconjug Chem 2012; xxx: xxx-xxx. [Epub ahead of print]
85. Yuan Q, Fu Y, Kao WJ, Janigro D, Yang H. Transbuccal Delivery of CNS Therapeutic Nanoparticles: Synthesis, Characterization, and In vitro Permeation Studies. ACS Chem Neurosci 2011; 2(11): 676-83.
86. Gosk S, Vermehren C, Storm G, Moos T. Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion. J Cereb Blood Flow Metab 2004; 24(11): 1193-204.
87. Karatas H, Aktas Y, Gursoy-Ozdemir Y, et al. A nanomedicine transports a peptide caspase-3 inhibitor across the blood-brain barrier and provides neuroprotection. J Neurosci 2009; 29(44): 13761-9.
88. Aktas Y, Yemisci M, Andrieux K, et al. Development and brain delivery of chitosan-PEG nanoparticles functionalized with the monoclonal antibody OX26. Bioconjug Chem 2005; 16(6): 1503-11.
89. Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cellpenetrating peptides. Biomaterials 2011; 32(26): 6194-203.
90. Qiu XQ, Wang H, Cai B, Wang LL, Yue ST. Small antibody mimetics comprising two complementarity-determining regions and a framework region for tumor targeting. Nat Biotechnol 2007; 25(8): 921-9.
91. Qian Y, Zha Y, Feng B, et al. PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phagedisplayed TGN peptide for brain-targeted gene delivery. Biomaterials 2013; 34(8): 2117-29.
92. Park K, Hong H-Y, Moon HJ, et al. A new atherosclerotic lesion probe based on hydrophobically modified chitosan nanoparticles functionalized by the atherosclerotic plaque targeted peptides. J Control Release 2008; 128(3): 217-23.
93. Yoo MK, Kang SK, Choi JH, et al. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010; 31(30): 7738-47.
94. Talvitie E, Leppiniemi J, Mikhailov A, Hytönen VP, Kellomäki M. Peptide-functionalized chitosan-DNA nanoparticles for cellular targeting. Carbohydr Polym 2012; 89(3): 948-54.
95. Jie LY, Cai LL, Wang LJ, et al. Actively-targeted LTVSPWY peptide-modified magnetic nanoparticles for tumor imaging. Int J Nanomedicine 2012; 7: 3981-9.
96. Yu J, Xie, Zheng, et al. Fabrication and characterization of nuclear localization signal-conjugated glycol chitosan micelles for improving the nuclear delivery of doxorubicin. Int J Nanomedicine 2012; 7: 5079-90.
97. Opanasopit P, Rojanarata T, Apirakaramwong A, Ngawhirunpat T, Ruktanonchai U. Nuclear localization signal peptides enhance transfection efficiency of chitosan/DNA complexes. Int J Pharm 2009; 382(1-2): 291-5.
98. Jayaraman MS, Bharali DJ, Sudha T, Mousa SA. Nano chitosan peptide as a potential therapeutic carrier for retinal delivery to treat age-related macular degeneration. Mol Vis 2012; 18: 2300-8.
99. Li C, Guo T, Zhou D, et al. A novel glutathione modified chitosan conjugate for efficient gene delivery. J Control Release 2011; 154(2): 177-88.
100. Jin X, Xu Y, Shen J, Ping Q, Su Z, You W. Chitosan-glutathione conjugate-coated poly(butyl cyanoacrylate) nanoparticles: Promising carriers for oral thymopentin delivery. Carbohydr Polym 2011; 86(1): 51-7.
101. Niu J, Su Z, Xiao Y, et al. Octreotide-modified and pH-triggering polymeric micelles loaded with doxorubicin for tumor targeting delivery. Eur J Pharm Sci 2012; 45(1-2): 216-26.
102. Yang Y, Liu X, Yu W, Zhou H, Li X, Ma X. Homogeneous synthesis of GRGDY grafted chitosan on hydroxyl groups by photochemical reaction for improved cell adhesion. Carbohydr Polym 2010; 80(3): 733-9.
103. Hansson A, Hashom N, Falson F, Rousselle P, Jordan O, Borchard G. In vitro evaluation of an RGD-functionalized chitosan derivative for enhanced cell adhesion. Carbohydr Polym 2012; 90(4): 1494-500.
104. Wang Y, Su W, Li Q, et al. Preparation and evaluation of lidocaine hydrochloride-loaded TAT-conjugated polymeric liposomes for transdermal delivery. Int J Pharm 2013; 441(1-2): 748-56.
105. Malhotra M, Tomaro-Duchesneau C, Prakash S. Synthesis of TAT peptide-tagged PEGylated chitosan nanoparticles for siRNA delivery targeting neurodegenerative diseases. Biomaterials 2013; 34(4): 1270-80.
106. Berry CC. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine (Lond) 2008; 3(3): 357-65.
107. Zhao A, Yao P, Kang C, Yuan X, Chang J, Pu P. Synthesis and characterization of tat-mediated O-CMC magnetic nanoparticles having anticancer function. J Magn Magn Mater 2005; 295(1): 37-43.
108. Vandenbroucke RE, De Smedt SC, Demeester J, Sanders NN. Cellular entry pathway and gene transfer capacity of TAT-modified lipoplexes. Biochim Biophys Acta 2007; 1768(3): 571-9.
109. Liang XF, Wang HJ, Luo H, et al. Characterization of novel multifunctional cationic polymeric liposomes formed from octadecyl quaternized carboxymethyl chitosan/cholesterol and drug encapsulation. Langmuir 2008; 24(14): 7147-53.
110. Wang H, Zhang S, Liao Z, et al. PEGlated magnetic polymeric liposome anchored with TAT for delivery of drugs across the blood-spinal cord barrier. Biomaterials 2010; 31(25): 6589-96.
111. Liu Y, Wang CY, Kong XH, et al. Novel multifunctional polyethylene glycol-transactivating-transduction protein-modified liposomes cross the blood-spinal cord barrier after spinal cord injury. J Drug Target 2010; 18(6): 420-9.
112. Rahmat D, Khan MI, Shahnaz G, Sakloetsakun D, Perera G, Bernkop-Schnürch A. Synergistic effects of conjugating cell penetrating peptides and thiomers on non-viral transfection efficiency. Biomaterials 2012; 33(7): 2321-6.
113. Bartneck M, Keul HA, Wambach M, et al. Effects of nanoparticle surface-coupled peptides, functional endgroups, and charge on intracellular distribution and functionality of human primary reticuloendothelial cells. Nanomedicine 2012; 8(8): 1282-92.
114. Han HD, Mangala LS, Lee JW, et al. Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles. Clin Cancer Res 2010; 16(15): 3910-22.
115. Du YZ, Cai, Ping L, et al. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells. Int J Nanomedicine 2011; 6: 3499-508.
116. Wang YY, Lu LX, Feng ZQ, Xiao ZD, Huang NP. Cellular compatibility of RGD-modified chitosan nanofibers with aligned or random orientation. Biomed Mater 2010; 5(5): 054112.
117. Wu J, Jiang Y, Yang W, et al. Dual Function of RGD-Modified VEGI-192 for Breast Cancer Treatment. Bioconjug Chem 2012; 23(4): 796-804.
118. Pashkunova-Martic I, Kremser C, Galanski M, et al. Lectin-Gdloaded chitosan hydrogel nanoparticles: a new biospecific contrast agent for MRI. Mol Imaging Biol 2011; 13(1): 16-24.
119. Liu J, Zhang L, Wang C, Xu H, Zhao X. Preparation and characterization of lectin-conjugated chitosan fluorescent nanoparticles. Mol Biosyst 2010; 6(6): 954-7.
120. Malik B, Goyal AK, Markandeywar TS, Rath G, Zakir F, Vyas SP. Microfold-cell targeted surface engineered polymeric nanoparticles for oral immunization. J Drug Target 2012; 20(1): 76-84.
121. Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012; 1820(3): 291-317.
122. Kadiyala I, Loo Y, Roy K, Rice J, Leong KW. Transport of chitosan-DNA nanoparticles in human intestinal M-cell model versus normal intestinal enterocytes. Eur J Pharm Sci 2010; 39(1- 3): 103-9.
123. Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 2001; 70(3): 399-421.
124. Dua P, Kim S, Lee DK. Nucleic acid aptamers targeting cellsurface proteins. Methods 2011; 54(2): 215-25.
125. Tallury P, Kar S, Bamrungsap S, Huang YF, Tan W, Santra S. Ultra-small water-dispersible fluorescent chitosan nanoparticles: synthesis, characterization and specific targeting. Chem Commun (Camb) 2009; 7(17): 2347-9.
126. Umemura M, Makimura Y, Itoh M, et al. One-step synthesis of efficient binding-inhibitor for influenza virus through multiple addition of sialyloligosaccharides on chitosan. Carbohydr Polym 2010; 81(2): 330-4.
127. Han J, Li X. Chemoenzymatic syntheses of sialyl Lewis X- chitosan conjugate as potential anti-inflammatory agent. Carbohydr Polym 2011; 83(1): 137-43.
128. Chen H, Li M, Wan T, et al. Design and synthesis of dual-ligand modified chitosan as a liver targeting vector. J Mater Sci Mater Med 2012; 23(2): 431-41.